At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 260 enrolled
Drug / intervention
AM-101drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
AM-101 in the Post-Acute Treatment of Peripheral Tinnitus 1 (AMPACT1) - an Open-Label Extension to the TACTT2 Study
In Brief
A Phase 3 clinical trial evaluating AM-101 for Tinnitus. Completed, enrolled 260 participants across 1 site.
Detailed Summary
The purpose of this research study is to test the safety and local tolerance of repeated treatment cycles of AM-101.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsTinnitus
CountriesUnited States
Collaborators--
Timeline
Phase 3CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedSep 2013
Enrollment StartJun 2014
Primary CompletionJan 2017
TodayJul 2026
First PostedSep 4, 2013
Enrollment StartJun 1, 2014
Primary CompletionJan 1, 2017
TodayJul 2, 2026
Enrollment to primary: 2.6 yearsPosted 12.8 years ago
Interventions
AM-101drug
AM-101 gel for intratympanic injection